Advertisement
Canada markets open in 5 hours 43 minutes
  • S&P/TSX

    21,873.72
    -138.00 (-0.63%)
     
  • S&P 500

    5,071.63
    +1.08 (+0.02%)
     
  • DOW

    38,460.92
    -42.77 (-0.11%)
     
  • CAD/USD

    0.7310
    +0.0012 (+0.17%)
     
  • CRUDE OIL

    82.92
    +0.11 (+0.13%)
     
  • Bitcoin CAD

    87,439.60
    -3,774.16 (-4.14%)
     
  • CMC Crypto 200

    1,388.98
    +6.41 (+0.46%)
     
  • GOLD FUTURES

    2,333.90
    -4.50 (-0.19%)
     
  • RUSSELL 2000

    1,995.43
    -7.22 (-0.36%)
     
  • 10-Yr Bond

    4.6520
    +0.0540 (+1.17%)
     
  • NASDAQ futures

    17,450.00
    -214.50 (-1.21%)
     
  • VOLATILITY

    16.28
    +0.31 (+1.94%)
     
  • FTSE

    8,078.25
    +37.87 (+0.47%)
     
  • NIKKEI 225

    37,628.48
    -831.60 (-2.16%)
     
  • CAD/EUR

    0.6818
    -0.0001 (-0.01%)
     

Analysts’ Recommendations for Vertex Pharmaceuticals

Analysts’ Recommendations for Vertex Pharmaceuticals

In February 2018, Vertex Pharmaceuticals (VRTX) announced the results of a Phase 2 trial for VX-150, an investigational NaV1.8 inhibitor. It had positive results in patients with acute pain after bunion removal and was well tolerated by patients.